Cell therapy for advanced solid tumors with specific proteins
Part of Cancer clinical trials.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You need advanced solid cancer (like stomach, colon, pancreas, or prostate) that has at least one tumor that can be measured on a scan.
- Your tumor must test positive for one of four specific proteins (Claudin 18.2, GCC, TROP2, or PSMA) at a moderate to strong level.
- You must have tried at least two standard treatments that didn't work, or be unable to get standard treatment.
- You need to be able to care for yourself (ECOG 0 or 1) and have adequate blood, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called CAR-DC for people with advanced solid tumors that have certain markers on their cells. It aims to see if it is safe and works against cancers like lung, liver, stomach, or colorectal cancer that haven't responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Hear when a new Advanced Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.